Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new biosimilars or generics in 2025, as featured in the latest edition of Fierce | This ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Amgen. Looking at options history for Amgen AMGN we detected 14 trades. If we consider the specifics of each trade ...

Amgen has also opened a new technology and innovation site in ... appeals court upheld a decision denying a stay on sales of biosimilar versions of its drug Eylea, impacting its competitive stance in ...

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance Image Source: Zacks Investment Research Amgen’s stock has been rising ...

Amgen has also opened a new technology and innovation ... denying a stay on sales of biosimilar versions of its drug Eylea, impacting its competitive stance in the biologics market.